Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.38 |
| ▸ | CCR4 | P51679 | 1/20 | 0.38 |
| ▸ | BUB1 | O43683 | 4/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611177 | 0.77 | KHK (0.40) | — | |
| SCHEMBL31089343 | 0.75 | SMN1; SMN2 (0.44) | CNR1CNR2NPBWR1PTGDR2 | |
| SCHEMBL16611335 | 0.73 | PTGS2 (0.49) | — | |
| SCHEMBL3772381 | 0.73 | CNR1 (0.41) | CNR1CNR2BUB1PTGER4 | |
| SCHEMBL3771429 | 0.73 | CNR1 (0.41) | CNR1CNR2BUB1PTGER4 | |
| SCHEMBL16611033 | 0.72 | CHRM3 (0.32) | — | |
| SCHEMBL21797105 | 0.72 | NPBWR1 (0.41) | NPBWR1GRIN1GRIN2BPDE1APDE1B | |
| SCHEMBL16611389 | 0.72 | AXL (0.33) | — | |
| SCHEMBL25289257 | 0.71 | ALDH1A1 (0.45) | CNR2NPBWR1GRIN1GRIN2BPDE1A | |
| SCHEMBL31140686 | 0.71 | ALDH1A1 (0.45) | CNR2NPBWR1GRIN1GRIN2BPDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | CNR1 3168/4885CNR2 2611/4885NPBWR1 3251/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | CNR1 3168/4885CNR2 2611/4885NPBWR1 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.